Longer, Shorter Interpregnancy Interval Tied to Higher ASD Risk

This article originally appeared here.
Share this content:
Longer, Shorter Interpregnancy Interval Tied to Higher ASD Risk
Longer, Shorter Interpregnancy Interval Tied to Higher ASD Risk

MONDAY, Sept. 14, 2015 (HealthDay News) -- Risk of autism spectrum disorder (ASD) may be higher in children born after interpregnancy intervals of less than two years or greater than six years, according to a study published online Sept. 14 in Pediatrics.

Ousseny Zerbo, Ph.D., from Kaiser Permanente Northern California (KPNC) in Oakland, and colleagues evaluated medical records data from a cohort of 45,261 children born at KPNC between 2000 and 2009 to determine the association between interpregnancy interval and ASD risk in second-born children.

The researchers found that children born after an interpregnancy interval of <12 months or ≥72 months had a two- to threefold increased risk of ASD compared with children born after an interval of 36 to 47 months. Adjusted hazard ratios (95 percent confidence intervals) were 3 (1.9-4.7) for an interpregnancy interval of less than six months, 2.1 (1.4-3.3) for an interpregnancy interval of six to eight months, 1.9 (1.3-2.1) for an interpregnancy interval of nine to 11 months, 1.5 (1.1-2.1) for an interpregnancy interval of 12 to 23 months and 2.4 (1.5-3.7) for an interpregnancy interval of at least 72 months. Maternal BMI, change in BMI between pregnancies, parental age, maternal antidepressant medication use, and unfavorable events occurring during the first or second pregnancy did not explain the results.

"The mechanism explaining this association is unknown, and more research is needed," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths